Klinicheskoe znachenie farmakologicheskogo vliyaniya na vospalenie v malykh dykhatel'nykh putyakh pri bronkhial'noy astme


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Small airways are involved in persistent inflammation and functional disorders in bronchial asthma (BA). The influence on distal lung inflammation is possible with the use of extra-fine inhaled glucocorticosteroids (ICS) and their combination with long-acting β-agonists (LABA), the clinical effect is achieved by using lower doses of ICS. Recent research on the efficacy of combined ICS/ LABA for BA patients in real-life clinical practice, and analysis of clinical efficacy of fixed combinations of ICS/LABA compared with ICS and LABA delivered in separate inhalers have demonstrated the benefits of extra-fine beclomethasone/formoterol compared with combinations of non extra-fine combinations of ICS/LABA for achieving BA control and quality of life of patients.

Full Text

Restricted Access

About the authors

N. M Nenasheva

References

  1. Balzar S, Wenzel SE, Chu HW. Transbronchial biopsy as a tool to evaluate small airways in asthma. Eur Respir J 2002;20:254-59.
  2. Sorkness RL, Bleecker ER, Busse WW, et al. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol 2008;104:394-403.
  3. Scichilone N, Battaglia S, Olivieri D, Bellia V. The role of small airways in monitoring the response to asthma treatment: what is beyond FEV1? Allergy 2009:64:1563-69.
  4. Contoli М, Bousquet J, Fabbri L, et al. The small airways and distal lung compartment in asthma and COPD: a time for reappraisal. Allergy 2010;65;141-51.
  5. Ненашева Н.М. Роль мелких дыхательных путей при бронхиальной астме//Атмосфера. Пульмонология и аллергология 2010. № 4. С. 30-35.
  6. Будневский А.В., Бурлачук В.Т., Олышева И.А. Терапевтические подходы к контролю воспаления на уровне мелких бронхов при бронхиальной астме // Российский аллергологический журнал 2010. № 9. С. 85-94.
  7. Huchon G, Magnussen H, Chuchalin A, et al. Lung function and asthma control with beclomethasone and formoterol in single inhaler. Respir Medicine 2009;103:41-9.
  8. Papi A, Paggiaro P, Nicolini G, et al. Beclometasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy 2007;62:1182-88.
  9. Papi A, Paggiaro P, Nicolini G, et al. Beclometasone/formoterol vs budesonide/formoterol combination therapy in asthma. Eur Respir J 2007;29:682-89.
  10. Barnes PJ, Nicolini G, Bizzi A, et al. Do inhaled corticosteroid/long-acting beta2-agonist fixed combinations provide superior clinical benefits compared with separate inhalers? A literature reappraisal. Allergy Asthma Proc 2012; 33:140-44.
  11. Global Initiative for Asthma. Available at: http:// www.ginasthma.com
  12. Greening AP, Ind PW, Northfield M, and Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994;344:219-24.
  13. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996,153:1481-88.
  14. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997;337:1405-11.
  15. Matz J, Emmett A, Rickard K, Kalberg C. Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: An analysis of asthma exacerbations. J Allergy Clin Immunol 2001;107:783-91.
  16. Bateman ED, Britton M, Carrillo J, et al. Salmeterol/fluticasone combination inhaler: A new, effective and well tolerated treatment for asthma. Clin Drug Investig 1998;16:193-201.
  17. Chapman KR, Ringdal N, Backer V, et al. Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: As effective as when given via separate Diskus inhalers. Can. Respir J 1999;6:45-51.
  18. Aubier M, Pieters WR, Schlosser NJ, Steinmetz KO. Salmeterol/fluticasone prorionate (50/500 vicrog) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respire Med 1999;93:876-84.
  19. Zetterstrom O, Buhl R, Mellem H, et al. Improved asthma control with budesonide/formoterol in a single inhaler compared with budesonide alone. Eur Respire J 2001;18:262-68.
  20. Rosenhall L, Heinig JH, Lindqvist A, et al. Budesonide/formoterol (Symbicort) is well tolerated and effective in patients with moderate persistent asthma. Int J Clin Pract 2002;56:427-33.
  21. Rosenhall L, Elvstrand A, Tilling B, et al. One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma. Respir Med 2003;97:702-08.
  22. Jenkins C, Kolarikova R, Kuna P, et al. Efficacy and safety of high-dose budesonide/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma. Respirology 2006;11:276-86.
  23. Chervinsky P, Baker J, Bensch G, et al. Patient-reported outcomes in adults with moderate to severe asthma after use of budesonide and formoterol administered via 1 pressurized metered-dose inhaler. Ann Allergy Asthma Immunol 2008;101:463-73.
  24. Bodzenta-Lukaszyk A, Pulka G, Dymek A, et al. Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler. Respir Med 2011;105:674-82.
  25. Fabbri LM, Nicolini G, Olivery D, et al. Inhaled beclometasone dipropionate/formoterol extrafine fixed combination in treatment of asthma: evidence and future perspectives. Expert Opinion Pharmacother 2008;9:479-90.
  26. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? Am J Respir Crit Care Med 2004;170:836-44.
  27. Gibson PG, Powell H, Ducharme FM. Differential effects of maintenance long-acting beta-agonist and inhaled corticosteroid on asthma control and asthma exacerbations. J Allergy Clin Immunol 2007;119:344-50.
  28. Scicchitano R, Aalbers R, Ukena D, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004;20:1403-18.
  29. Черняк Б.А. Клиническая практика ведения больных бронхиальной астмой в России: результаты мониторинга // Атмосфера. Пульмонология и аллергология 2009. № 3. С. 23-28.
  30. Demoly P, Gueron B, Annunziata K, et al. Update on asthma control in five European countries: results of a 2008 survey Eur Respir Rev 2010;19:150-57.
  31. Haughney J, Price D, Kaplan A, et al. Achieving asthma control in practice: understanding the reasons for poor control. Respir Med 2008 102(12):1681-93.
  32. Muller V, Galffy G, Eszes N, et al. Asthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation. BMC Pulmonary Medicine 2011 11:40-5.
  33. Allegra L, Cremonesi G, Girbino G, et al. Real-life prospective study on asthma control in Italy: Cross-sectional phase results. Respiratory Medicine (2011), doi: 10.1016/j. rmed.2011.10.001
  34. De Backer W, Devolder A, Poli G, et al. Lung Deposition of BDP/Formoterol HFA pMDI in Healthy Volunteers, Asthmatic, and COPD Patients. J Aerosol Med Pulm Drug Delivery 2010;23:1-12.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies